Cannabinoids and Parkinson’s disease
Parkinson’s is a degenerative disease that primarily affects the central nervous system. At the cellular level, it is characterized by the destruction of dopamine-producing cells, also known as neurotransmitters ( NT ), leading to a loss of motor skills, including involuntary movements known as dyskinesia , etc.
Dopamine-producing cells are located in the reticulated part of the substantia nigra, which is an area where cannabinoid receptors are grouped together. These CBD receptors are attributed to beneficial medicinal effects, including reducing dyskinesia induced by L – DOPA and lessening body rigidity and involuntary bodily movements.
Effects of cannabinoids
- Reduction of dyskinesia
- Neuroprotective effects
- Decreased tremors
The improvement of dyskinesia is one of the effects most valued by Parkinson’s disease patients. The results of the studies conducted suggest that cannabinoids may offer some benefit in terms of improved motor functions as well as a neuroprotective effect.
Interaction of Cannabinoids to Parkinsons
The traditional treatment for Parkinson’s disease can induce side effects such as dementia, depression and cognitive impairment. However, clinical trials have proven cannabinoids to be an effective a treatment for Parkinson’s disease without causing the harm that derives from traditional medication. With the use of CBD, our patients’ quality of life is continuously improving without any psychiatric effects 
Scientific evidence indicates that cannabinoids contain therapeutic value in some associated disorders due to the reduction of dyskinesia, which is a form of tremor and dystonia induced by L-DOPA in parkinson’s disease. These cannabinoids aid in the reduction of tics in Tourette’s syndrome and hypokinetic parkinsonian syndromes. 
Bibliography for Parkinson’s disease and Cannabinoids
 Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial J Psychopharmacol November 2014 28:1088-1098, first published on September 18, 2014
 Müller-Vahl KR1, Kolbe H, Schneider U, Emrich HM. Cannabis in movement disorders Forsch Komplementarmed. 1999 Oct;6 Suppl 3:23-7.
Use cannabinoids for